Of the 5567 individuals in the vaccine group who were assessed for immunogenicity, 52 percent were seronegative at baseline, of whom 99.9 percent underwent seroconversion after vaccination; 87 percent of these who had been seronegative at baseline and received three doses of the hepatitis E vaccine remained seropositive by the end of month 54 . The seroconversion rates were similar among individuals who were seronegative at baseline and received either one, two, or three dosages of the hepatitis E vaccine.The active-treatment and placebo groups didn’t differ significantly with respect to geographic location, age, sex, Fitzpatrick skin type, lesion count at baseline, presence or lack of a history of skin cancer, or use or non-use of other therapies . A total of 547 patients were signed up for the two studies involving lesions on the facial skin or scalp, with 277 randomly assigned to get ingenol mebutate gel and 270 assigned to receive placebo . A total of 3 patients in the ingenol mebutate group discontinued the analysis early: 1 had an adverse event and 2 withdrew consent. In the placebo group, 8 patients discontinued the analysis early: 6 withdrew consent, 1 had a detrimental event , and 1 had a protocol deviation .